• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 4:46:28 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITRM alert in real time by email
    SC 13G/A 1 tm216363d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Iterum Therapeutics plc

    (Name of Issuer)

     

    Ordinary Shares, $0.01 par value per share

    (Title of Class of Securities)

     

    G6333L 101

    (CUSIP Number)

     

    ___________February 9, 2021__________

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G6333L 101


    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨ 

     

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

     

    CUSIP No. G6333L 101


    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

     

    CUSIP No. G6333L 101


    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

     

    CUSIP No. G6333L 101


    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

    Item 1(a).Name of Issuer:

     

    Iterum Therapeutics plc (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin, Ireland

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, $0.01 par value per share (“Ordinary Shares”)

     

    Item 2(e).CUSIP Number:

     

    G6333L 101

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (e) RA Capital Management, L.P. is a registered investment adviser and is filing this statement in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (g) Peter Kolchinsky and Rajeev Shah are control persons and are filing this statement in accordance with §240.13d-1(b)(1)(ii)(G).

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund and the Account. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Ordinary Shares reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Exhibits

     

    1Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on December 2, 2020.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2021

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.  
           
    By: RA Capital Healthcare GP, LLC  
           
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $ITRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITRM

    DatePrice TargetRatingAnalyst
    7/27/2021Sell → Hold
    Gabelli & Co.
    7/26/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $ITRM
    SEC Filings

    See more
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      5/19/25 7:15:09 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Iterum Therapeutics plc

      10-Q - Iterum Therapeutics plc (0001659323) (Filer)

      5/13/25 7:30:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      5/13/25 7:15:09 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Whalen Joseph John

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      3/18/25 8:00:04 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hunt Ronald

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      1/23/25 6:30:04 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dunne Michael W. converted options into 106,247 units of Ordinary Shares, increasing direct ownership by 93% to 220,001 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      8/12/24 9:00:05 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iterum Therapeutics upgraded by Gabelli & Co.

      Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold

      7/27/21 11:35:29 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral

      7/26/21 12:19:14 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics upgraded by Gabelli & Co

      Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold

      5/28/21 8:38:55 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

      DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin

      12/13/21 8:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

      Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade

      3/16/21 7:30:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

      SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 7:54:21 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 3:31:48 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      1/31/24 4:55:45 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iterum Therapeutics Announces Extension of Term of Promissory Note

      DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. ("Pfizer") has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029. "We are very pleased to announce that Pfizer has agreed to extend the due date for payment of the regulatory milestone associated with ORLYNVAH™'s approval by the FDA," said Corey Fishman, Iterum's Chief Executive Officer. "The $20.0 milli

      5/19/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Reports First Quarter 2025 Financial Results

      --Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. "Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAHTM for the treatment of uncomplicated urinary tract infections (uUTIs) by the fourth quarter of th

      5/13/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

      DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access

      5/6/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Financials

    Live finance-specific insights

    See more
    • Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

      DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access

      5/6/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      --ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. "While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial u

      2/7/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

      DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2024 financial results before the open of the U.S. financial markets on Friday, February 7, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) a

      1/31/25 8:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dunne Michael W. bought $35,000 worth of Ordinary Shares (25,000 units at $1.40), increasing direct ownership by 28% to 113,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/27/23 9:00:06 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $18,442 worth of Ordinary Shares (10,000 units at $1.84), increasing direct ownership by 13% to 88,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/19/23 4:15:25 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $40,690 worth of Ordinary Shares (20,000 units at $2.03), increasing direct ownership by 34% to 78,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      11/27/23 5:00:19 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care